Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Styliani Polia"'
Autor:
Dimitrios T Boumpas, Antonis Fanouriakis, George Bertsias, Dionysis Nikolopoulos, Anastasia Filia, Myrto Nikoloudaki, Panagiotis Garantziotis, Ricardo Grieshaber-Bouyer, George Sentis, Dimitra Nikoleri, Georgia-Savina Moysidou, Stavros Doumas, Styliani Polia
Publikováno v:
Lupus Science and Medicine, Vol 11, Iss Suppl 1 (2024)
Externí odkaz:
https://doaj.org/article/07bbf46db80b40879a11a65c1983be4d
Autor:
George Bertsias, Nikolaos Kougkas, Prodromos Sidiropoulos, N. Avgustidis, M. Terizaki, Irini Flouri, Christina Adamichou, A. Eskitzis, P Kyfonidou, Aggeliki Kountouri, Styliani Polia, Ainour Molla Ismail Sali, Argyro Repa
Publikováno v:
Spondyloarthritis – treatment.
Background Data regarding effectiveness and persistence to therapy with anti-IL17 agent secukinumab (SEC) in spondyloarthritis (SpA) patients of real world clinical practice are very limited. Objectives To assess characteristics of SpA patients start
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::750af8fc6f05cf6fe92893ec843fe9ee
https://doi.org/10.1136/annrheumdis-2019-eular.7877
https://doi.org/10.1136/annrheumdis-2019-eular.7877
Autor:
Prodromos Sidiropoulos, N. Avgustidis, Irini Flouri, Nikolaos Kougkas, Styliani Polia, George Bertsias, Argyro Repa, A. Eskitzis, Ioannis Papalopoulos, Ainour Molla Ismail Sali
Publikováno v:
SATURDAY, 15 JUNE 2019.
Background: Interstitial lung disease (ILD) is the most significant pulmonary manifestation of Rheumatoid Arthritis (RA)[1], contributing to decreased quality of life, progressive chronic disability and high utilization of healthcare resources. Treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8eb074731f7176a089f1888e446df216
https://doi.org/10.1136/annrheumdis-2019-eular.6828
https://doi.org/10.1136/annrheumdis-2019-eular.6828
Autor:
P Verginis, Irini Gergianaki, Styliani Polia, Katerina Gkirtzimanaki, G. Bertsias, S Georgakis, G. Papadaki, Christina Adamichou, Prodromos Sidiropoulos
Publikováno v:
Oral presentations.
Background Interleukin (IL)-33 is a cell necrosis-derived alarmin with immunostimulatory properties which depend on the context of immune cells and the inflammatory milieu (1). In Systemic Lupus Erythematosus (SLE), extracellular DNA (as in extracell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f855145204a83bfdeea1fc2ea93ae98d
https://doi.org/10.1136/annrheumdis-2018-ewrr2018.3
https://doi.org/10.1136/annrheumdis-2018-ewrr2018.3